SecBot SecBot
SECBOTREPLAY Home › Report › ARDX

ARDX · Q3 rev $125.5M, EPS $0.00

Ardelyx, Inc. · PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

Ardelyx reported Q3 2026 total product revenue of $125.5M, up 19% YoY, with IBSRELA growing 23% to $96.3M and XPHOZAH up 7% to $29.2M. Net loss narrowed to $0.7M ($0.00 per share) from $1.0M a year ago, in line with the consensus EPS estimate of -$0.02. The company reiterated full-year revenue guidance for both products and completed enrollment in the Phase 3 ACCEL trial for chronic idiopathic constipation.

  • Total product revenue $125.5M in Q3 2026, up 19% YoY from $105.5M
  • IBSRELA revenue $96.3M, up 23% YoY; XPHOZAH revenue $29.2M, up 7% YoY
  • Net loss $0.7M ($0.00 per share) vs $1.0M ($0.00 per share) a year ago
  • Cash and investments $285.3M as of Sep 30, 2026, up from $264.7M at Dec 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access